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With better matching due to genomic tissue typing and improved
immunosuppression, hematopoietic stem cell transplant (HSCT)
usingHLA-matched unrelated donors (URD) have similar outcome
as using HLA-identical sibling donors (sib). Do some leukemia pa-
tients benefit from an URD transplant, because of a stronger graft-
versus-leukemia (GVL) effect? We analyzed the outcome in 941
URD (8/8 HLA-allele matched) transplants, compared to 3158
sib HSCT for acute leukemia (AML and ALL) and chronic myeloid
leukemia (CML) receiving myeloablative conditioning between
1995–2004 and reported to the CIBMTR. Transplant-related mor-
tality (TRM), relapse, survival and leukemia-free-survival (LFS)
were compared for each disease. In a Cox proportional hazard re-
gression model including variables important for outcome, acute
and chronic GVHD were added as time-dependent variables.
Results:Using URD vs. sib HSCT, TRMwas increased in early
AML (40% vs. 24%, p5 0.001), and advanced ALL or AML (44%
vs. 31%, p 5 0.01). Among other risk factors, TRM was associated
with URD (p\0.001), advanced disease and increasing donor and
recipient age. Relapse was similar using URD or sib donors; AML
CR1 (5-year relapse 22% vs. 15%), intermediate disease (21% vs.
22%), advanced (43% vs. 46%), ALL early (15% vs. 23%), interme-
diate (36% vs. 32%) and advanced (48% vs. 52%), and for CML
early (5% vs. 6%), intermediate disease (16% vs. 22%) and blast cri-
sis (39% vs. 35%) (ns). In the Cox model, relapse was decreased in
patients with chronic GVHD for AML and ALL and in patients
with acute GVHD for CML. LFS was decreased in AML CR1
and advanced disease, and CML in blast crisis in URD vs. sib trans-
plants.To Conclude: Relapse was the same using URD compared
to sib HSCT, suggesting similar GVL effect. TRM was increased
and LFS was decreased using URD. Therefore, a sib donor should
be the first choice.
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CHARACTERIZATION OF B CELL TARGET ANTIGENS IN PATIENTS WITH
CHRONIC GRAFT VERSUS HOST DISEASE
Sarantopoulos, S.1, Bhuiya, N.S.1, Cutler, C.S.1, Wu, C.J.1,2,
Brusic, V.2, Soiffer, R.J.1, Antin, J.H.1, Ritz, J.1. 1Dana-Farber Cancer
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Patients with chronic graft versus host disease (cGVHD) develop
antibody responses against a variety of target antigens 4–8 months
after hematopoietic stem cell transplantation (HSCT). These anti-
bodies can be specifically directed against amino acid polymor-
phisms that distinguish recipient from donor proteins (allo-
antibodies) or against normal or tumor-associated proteins that
are identical in the recipient and donor (auto-antibodies). We
used high-density protein microarrays (ProtoArray Protein Micro-
arrays V4, Invitrogen) to define the spectrum of antibody targets in
patients with cGVHD after HSCT. These protoarrays contain over
8,000 unique proteins individually spotted on nitrocellulose-coated
slides under native conditions. We used 1-year post-HSCT plasma
from 10 patients with cGVHD for antibody profiling. The reactiv-
ity of each patients cGVHD plasma was compared to a sample ob-
tained from the same patient prior to HSCT as well as to the
patients donor. All 30 arrays were from the same lot and were pro-
cessed by the same operator to enhance consistency. Plasma was
tested at a dilution of 1:500 and results were analyzed using Proto-
Array Prospector software (InVitrogen). Overall, 98 proteins were
targeted by cGVHDplasma and not by any of the pre-HSCTor do-
nor samples. Only 4 of the 98 proteins were targeted by 2 or more
cGVHD patients: protein kinase D3 (nu), ribonucleoprotein auto-
antigen (Ro/SSA), aldehyde dehydrogenase 7, and pyruvate dehy-
drogenase E1 component alpha subunit. Several proteins
identified by cGVHD antibodies were surface membrane or se-
creted proteins. These include PDGFR-alpha, PDGFR-beta,
FGFR-3, FGFR1 oncogene partner, adrenergic-beta receptor ki-
nase, poliovirus-receptor related-3, liprin beta-2, PMEPA1/
STAG1, neuropeptide-Y and serpin peptidase inhibitor. Antibodiesto these targets may have direct activating or inhibitory functional
effects or may initiate lysis of target cells through complement-me-
diated killing or antibody dependent cellular cytotoxicity. These ef-
fects can occur independently of effector T cell responses to these
proteins. These results demonstrate that patients with cGVHD de-
velop antibodies specific for a largely unique spectrum of target an-
tigens. These target antigens include surface membrane and
secreted proteins with potential functional capacities and this may
explain why B cell-directed therapy can improve some clinical man-
ifestations of cGVHD.
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TREATMENT
Sarantopoulos, S.1, Stevenson, K.E.2, Kim, H.T.2, Bhuiya, N.S.1,
Cutler, C.S.1, Alyea, E.P.1, Ho, V.T.1, Soiffer, R.J.1, Antin, J.H.1,
Ritz, J.1. 1Dana-Farber Cancer Institute, Boston, MA; 2Dana-Farber
Cancer Institute, Harvard Medical School, Boston, MA.
We recently showed that high levels of B cell Activating Factor
(BAFF) after allogeneic hematopoietic stem cell transplantation
(HSCT) are associated with the development of chronic graft versus
host disease (cGVHD). Clinical responses observed after treatment
with rituximab (anti-CD20) also suggest a role for B cells in the im-
mune pathology of cGVHD, but the effect of rituximab on BAFF
levels and B cell repertoire in patients with cGVHD is unknown.
In patients with autoimmune disease treated with rituximab,
BAFF levels are elevated for 1–2months after B cell depletion. Since
high BAFF promotes survival and differentiation of human B cell
receptor (BCR)-activated (CD271) B cells into Ig-secreting cells
there is concern that high BAFF after rituximab may contribute
to clinical relapse. We studied 20 patients who received rituximab
(375 mg/m2/week  4 consecutive weeks for one or two cycles)
for steroid-refractory cGVHD. Patients were tested a median of
25 months after starting treatment. At the time of analysis, 9 had
progressive cGVHD, defined as worsening signs or symptoms in
any organ system or the requirement of additional systemic therapy
and 11 had stable or improved cGVHD, measured by reduction in
immune suppression and overall clinical assessment. While median
CD191 B cell number did not differ prior to rituximab treatment
(104.5  106/L versus 203.7  106/L, p 5 0.60, respectively),
CD191B cell number was significantly lower in the 9 patients
with worsening cGVHD at 25 months. Median BAFF levels were
also significantly higher in this group. To examine whether high
BAFF levels affected B cells in these patients, we examined BAFF-
R expression on CD191 B cells by flow cytometry. The median
fluorescence intensity (MFI) of BAFF-R expression was lower in
the progressive disease group compared to the stable/improved
group (0.62 versus 1.67 MFI, respectively). Finally, patients with
progressive cGVHD had increased proportions of CD271 B cells,
indicating that the pool of circulating B cells contains a higher frac-
tion of activated cells in these patients (Table 1). Despite persistent
B lymphopenia after rituximab, patients with progressive cGVHD
had significantly higher BAFF levels associated with a significant in-
crease in the proportion of CD271 BCR-activated circulating B
cells. These data provide a rationale for investigation of BAFF an-
tagonists in the treatment of cGVHD.BAFF levels & B cell phenotype 25 months after rituximab therapy for
cGVHD
Stable/Improved Progressed
(n 5 11) (n 5 9) p-valueTotal B Cell No.
(106)/L124.7 3.8 0.002BAFF (ng/ml) 2.58 7.72 0.01
% BAFF-R on B Cells 68.4 2.2 0.004
% CD27 on B Cells 9.0 70.9 0.04
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Since most HSC transplants using unrelated donors have HLA
mismatches between the recipient and donor, better approaches
for identifying the optimal donor amongst several mismatched can-
didates would be a major advance. The long-term goal of this inves-
tigation is to rank HLA disparities according to their effects on
transplant outcomes. In this report, HLA-A is used as a model to
characterize HLA disparities and examine outcomes for the most
frequent disparities. Unrelated donor-recipient pairs (n 5 4221)
who received myeloablative predominantly marrow (92%)trans-
plants for hematological malignancies (AML, ALL, CML, MDS
and NHL) through the NMDP between 1990 and 2002 were stud-
ied. High resolution HLA typing was performed for HLA-A, -B, -
C, -DRB1, -DQA1, -DQB1, -DPA1 and -DPB1. When HLA-A, -
B, -C and -DRB1 were matched, overall survival was the same if
pairs were also matched for HLA-DQ and -DP (reference), had
HLA-DP mismatches (OR 1.00, CI 0.84–1.18), or had HLA-DP
and/or -DQ mismatches (OR 1.01, CI 0.80–1.29). These groups
were combined to create the reference group for subsequent com-
parisons. Transplants with a single HLA-A disparity (n 5 317)
were associated with increased mortality (OR 1.32, CI 1.07–1.63).
The most frequent single HLA-A mismatches were HLA-
A*0201-*0205 (n 5 28), HLA-A *0301-*0302 (n 5 15), HLA-A
*0201-*0206 (n 5 15), HLA-A *0201-*6801 (n 5 12), HLA-
A*0101-*1101 (n 5 11), HLA-A*0101-*0201 (n 5 9), and HLA-
A*2402-*2403 (n5 9). Considering p5 0.01 as a threshold for sig-
nificance with multiple comparisons, there were no statistically sig-
nificant relationships between any of these disparities and transplant
outcomes. Table 1 shows the observations for the most interesting
mismatches for grades 3–4 acute GvHD: A*2402–2403 (p5 0.034)
and A*0201–0206 (p 5 0.033). There were no significant relation-
ships detected for engraftment, chronic GvHD, relapse, trans-
plant-related mortality, or disease-free survival. Using these data,
it is estimated that more than 15,000 subjects would be required
to achieve 80% power to detect an effect on survival for a particular
HLA-A disparity (assuming similar HLA-A frequencies). To over-
come this barrier, a novel system for rankingHLA disparities which
uses the structural basis for allorecognition is proposed.
Table 1. Frequent HLA-A Disparities and Transplant Outcomes
HLA Mismatch Severe Acute GvHD SurvivalA*2402-2403 OR 4.70 (CI 0.91–30.4) OR 3.02 (CI 0.56–16.3)
A*0201-0206 OR 3.22 (CI 1.02–10.50) OR 2.64 (CI 0.81–8.38)37
CYTOTOXIC T LYMPHOCYTES (CTL) SPECIFIC FOR MULTIPLE VIRUSES
CAN BE GENERATED FROM UMBILICAL CORD BLOOD FOR ADOPTIVE
IMMUNOTHERAPY
Bollard, C.M.1, Khalil, M.1, Leen, A.M.1, Cruz, C.R.1, Decker, W.2,
Dotti, G.1, Molldrem, J.J.2, Rooney, C.M.1, Heslop, H.E.1,
Shpall, E.J.2. 1Baylor College of Medicine, Houston, TX; 2University
of Texas MD Anderson Cancer Center, Houston, TX.
Umbilical cord blood (UCB) transplantation is a promising alter-
native source of hematopoietic stem cells for patients lacking HLA-
matched donors. Nearly 60% of UCB transplants to date have been
performed on minority individuals for whom an unrelated donor
was not available; moreover, the naı¨ve phenotype of UCB cells is re-sponsible for the lower incidence and reduced severity of GvHD in
these patients. Still, relatively low cell numbers in UCB grafts have
lead to delayed immune reconstitution and higher mortality due to
infection. Reactivation of latent viruses such as CMV and EBV are
particularly problematic, as is overt infection from adenovirus
(Adv). Previous studies have shown that prophylactic adoptive im-
munotherapy with peripheral blood-derived CTL directed against
EBV, CMV and Adv can effectively prevent the clinical manifesta-
tions of these viruses after hematopoietic stem cell transplant. We
now hypothesize that generating virus-specific CTL from UCB
for adoptive immunotherapy will restore anti-viral immunity and
reduce viral infection postUCB transplant. Our aimwas to generate
multi-virus specific CTL fromUCBmononuclear cells using a clin-
ical-grade recombinant adenovirus type 5 vector pseudotyped with
a type 35 fiber carrying a transgene for CMVpp65. With this
Ad5f35pp65 vector we transduced UCB-derived dendritic cells to
use as antigen presenting cells to stimulate virus-specific CTL fol-
lowed by 2 rounds of weekly stimulation with autologous UCB-de-
rived EBV-lymphoblastoid cell lines (LCL) transduced with the
same vector. After 3 rounds of stimulation, 5 CTL cultures con-
tained a mean of 87% (range 81–94%) CD81ve and a mean of
26% (range 12–40%) CD41ve cells. Evaluable CTL lines showed
significant cytotoxicity in chromium release assays against non-
transduced autologous LCL and LCL infected with the
Ad5f35pp65 and Ad5f35 vectors. The observed cytotoxicity was
specific because transduced and non-transducedMHC-mismatched
LCL were not killed. ELISPOT assays on CTL demonstrated
a mean of 260 (range 45–694) and 47 (range 0–128) numbers of cells
secreting IFNg following incubation with CMVpp65 and Adv
hexon peptides respectively. No significant response to CMVIE1
peptides was demonstrated. These results show that, despite the
generally naı¨ve nature of UCB lymphocytes, multi-virus-specific re-
sponses can be expanded in vitro, and could potentially be used clin-
ically inUCBTpatients who develop infectious complications prior
to immune reconstitution.
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ALLOANERGIZED HLA-MISMATCHED BONE MARROW TRANSPLANTA-
TION – LOW INCIDENCE OF CLINICALLY SIGNIFICANT GVHD AND VIRAL
INFECTION RESULTING IN LONG TERM DISEASE FREE SURVIVAL
Davies, J.1, Gribben, J.1, Brennan, L.2, Nadler, L.1, Guinan, E.2. 1Dana
Farber Cancer Institute, Boston, MA; 2Dana Farber Cancer Institute,
Boston, MA.
We have previously reported early results of a clinical study of
HLA-mismatched related donor bone marrow transplantation
(BMT) after ex vivo stimulation with recipient alloantigens and
co-stimulatory blockade (CSB) to induce allospecific anergy (hypo-
responsiveness) in donor T cells. We now report the long-term fol-
low-up of a larger cohort of 24 pediatric and adult patients (median
age 11 years (range 0.5–50) with high-risk hematological malignan-
cies or bone marrow failure syndromes who received HLA-mis-
matched alloanergized BMT from related donors. After
myeloablative conditioning with cyclophosphamide and total
body irradiation, patients received donor bone marrow that had
been incubated with irradiated recipient peripheral blood mononu-
clear cells and monoclonal antibodies blocking CD28-mediated co-
stimulation. 21 of 22 evaluable patients engrafted (95%) and all
achieved full donor chimerism by D 1 21. No secondary graft fail-
ure occurred. Despite receiving a median of 2.8  107/kg CD31
donor T cells (range 0.7–6.8), only 2/21 evaluable patients (10%)
developed steroid-refractory acute graft versus-host-disease
(GvHD), with only one death attributable to acute GvHD. Five
of 11 seropositive patients reactivated CMV, but only one required
extended antiviral treatment. No deaths were attributable to CMV
or other viral infections. Only 1/12 evaluable patients (8%) devel-
oped chronic GvHD, which resolved with conventional immuno-
suppressive therapy. Eight recipients (33%) of full haplotype-
mismatched BMT survive disease-free with no chronic GvHD
and with normal performance scores with a median follow-up of 8
years. HLA-mismatched alloanergized BMT is thus associated
with a low incidence of clinically significant viral infections and ste-
roid-refractory acute GvHD. Furthermore, this strategy is associ-
ated with a very low incidence of chronic GvHD, and results in
long-term failure-free survival with good quality of life in
